Victoria Manax Rutson M.D. is a medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry with a focus on global drug/device/diagnostic development, nanomedicines, novel immunotherapies, and product launch/commercialization.  Dr. Manax has made indelible contributions to the field with her expertise in shaping clinical trial landscapes, particularly in adaptive platform designs with biomarker integration from Phase I-IV.   She has most recently joined Eckuity Capital as a partner. Dr. Manax has played a pivotal role in the development, approval, and launch of billion-dollar products, including the standards of care for breast cancer, lung cancer, and most recently, pancreatic cancer.  She has held multiple executive medical positions in companies including Abraxis Bioscience and Celgene (BMS).  In addition to her pharmaceutical expertise, she was the inaugural Chief Medical Officer for the Pancreatic Cancer Action Network. She has effectively overseen numerous multimillion-dollar global clinical trial programs, holds multiple clinical advisories, chair positions, and patents, exemplifying her commitment to advancing medical science and patient well-being. She is an internationally recognized speaker from programs through Harvard Business School and is a proud Belfast Ambassador recipient. Dr. Manax has received multiple distinguished honors including Who’s Who in Healthcare and was recently named as a government advisor to Northern Ireland for Health and Life Sciences.